Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

NCT01306422 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2011-03-01

No results posted yet for this study

Summary

The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or 15-days.

Conditions

Interventions

OTHER

Hoodia gordonii purified extract (H.g.PE)

H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days

OTHER

Placebo yogurt drink

Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.

OTHER

Placebo yogurt drink

Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch

OTHER

Placebo yogurt drink

Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner

OTHER

Hoodia gordonii purified extract (H.g.PE)

H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch

OTHER

Hoodia gordonii purified extract (H.g.PE)

H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner

Sponsors & Collaborators

  • Phytopharm

    collaborator INDUSTRY
  • Covance

    collaborator INDUSTRY
  • Unilever R&D

    lead INDUSTRY

Principal Investigators

  • Debra Mandarino, MD · Covance CRU, Madison WI

  • Leo Abrahamse, PhD · Unilever R&D Vlaardingen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-07-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306422 on ClinicalTrials.gov